Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 2
1992 4
1993 7
1994 7
1995 40
1996 26
1997 32
1998 42
1999 57
2000 73
2001 70
2002 85
2003 84
2004 91
2005 62
2006 71
2007 65
2008 59
2009 61
2010 52
2011 64
2012 67
2013 61
2014 46
2015 58
2016 32
2017 30
2018 24
2019 25
2020 11
2021 9
Text availability
Article attribute
Article type
Publication date

Search Results

1,320 results
Results by year
Filters applied: . Clear all
Page 1
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group. Dahlöf B, et al. Lancet. 2002 Mar 23;359(9311):995-1003. doi: 10.1016/S0140-6736(02)08089-3. Lancet. 2002. PMID: 11937178 Clinical Trial.
New-onset diabetes was less frequent with losartan. Interpretation Losartan prevents more cardiovascular morbidity and death than atenolol for a similar reduction in blood pressure and is better tolerated. Losartan seems to confer benefits beyond reduction in …
New-onset diabetes was less frequent with losartan. Interpretation Losartan prevents more cardiovascular morbidity and death t …
Pharmacokinetic and haemodynamic interactions between amlodipine and losartan in human beings.
Park JW, Kim KA, Il Kim Y, Park JY. Park JW, et al. Basic Clin Pharmacol Toxicol. 2019 Oct;125(4):345-352. doi: 10.1111/bcpt.13244. Epub 2019 May 27. Basic Clin Pharmacol Toxicol. 2019. PMID: 31058419 Free article. Clinical Trial.
The pharmacokinetics of amlodipine, losartan and EXP-3174, an active metabolite of losartan, were assessed at steady-state. ...Combination use of two drugs caused additive haemodynamic changes compared to treatment of amlodipine or losartan alone. The co-admi …
The pharmacokinetics of amlodipine, losartan and EXP-3174, an active metabolite of losartan, were assessed at steady-state. .. …
Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial.
Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, Riegger GA, Malbecq W, Smith RD, Guptha S, Poole-Wilson PA; HEAAL Investigators. Konstam MA, et al. Lancet. 2009 Nov 28;374(9704):1840-8. doi: 10.1016/S0140-6736(09)61913-9. Epub 2009 Nov 16. Lancet. 2009. PMID: 19922995 Clinical Trial.
With 4.7-year median follow-up in each group (IQR 3.7-5.5 for losartan 150 mg; 3.4-5.5 for losartan 50 mg), 828 (43%) patients in the 150 mg group versus 889 (46%) in the 50 mg group died or were admitted for heart failure (hazard ratio [HR] 0.90, 95% CI 0.82-0.99; …
With 4.7-year median follow-up in each group (IQR 3.7-5.5 for losartan 150 mg; 3.4-5.5 for losartan 50 mg), 828 (43%) patients …
Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.
Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B. Pitt B, et al. Lancet. 2000 May 6;355(9215):1582-7. doi: 10.1016/s0140-6736(00)02213-3. Lancet. 2000. PMID: 10821361 Clinical Trial.
We did the ELITE II Losartan Heart Failure Survival Study to confirm whether losartan is superior to captopril in improving survival and is better tolerated. ...Patients, stratified for beta-blocker use, were randomly assigned losartan (n=1,578) titrated to 5 …
We did the ELITE II Losartan Heart Failure Survival Study to confirm whether losartan is superior to captopril in improving su …
Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.
Lee SE, Kim YJ, Lee HY, Yang HM, Park CG, Kim JJ, Kim SK, Rhee MY, Oh BH; Investigators. Lee SE, et al. Clin Ther. 2012 Mar;34(3):552-568, 568.e1-9. doi: 10.1016/j.clinthera.2012.01.024. Epub 2012 Mar 3. Clin Ther. 2012. PMID: 22381711 Clinical Trial.
The incidence of ADRs were 7.84% and 10.40% in the fimasartan and losartan groups, respectively (chi(2) test, P = 0.3181). The efficacy of fimasartan was maintained over 24 weeks, and its tolerability was comparable with losartan in the extension study. CONCLUSIONS: …
The incidence of ADRs were 7.84% and 10.40% in the fimasartan and losartan groups, respectively (chi(2) test, P = 0.3181). The effica …
Comparison of losartan and amlodipine effects on the outcomes of patient with COVID-19 and primary hypertension: A randomised clinical trial.
Nouri-Vaskeh M, Kalami N, Zand R, Soroureddin Z, Varshochi M, Ansarin K, Rezaee H, Taghizadieh A, Sadeghi A, Ahangari Maleki M, Esmailnajad A, Saleh P, Haghdoost M, Maleki M, Sharifi A. Nouri-Vaskeh M, et al. Int J Clin Pract. 2021 Jun;75(6):e14124. doi: 10.1111/ijcp.14124. Epub 2021 Mar 13. Int J Clin Pract. 2021. PMID: 33650197 Free PMC article. Clinical Trial.
The length of hospital stay in losartan and amlodipine groups was 4.57 2.59 and 7.30 8.70 days, respectively (P value = .085). ...The 30-day mortality was two and five patients in losartan and amlodipine groups, respectively (P value = .241). CONCLUSIONS: There was …
The length of hospital stay in losartan and amlodipine groups was 4.57 2.59 and 7.30 8.70 days, respectively (P value = .085). ...The …
Losartan in diabetic nephropathy.
Carswell CI, Goa KL. Carswell CI, et al. Drugs. 2003;63(4):407-14; discussion 415-6. doi: 10.2165/00003495-200363040-00006. Drugs. 2003. PMID: 12558462 Review.
Losartan is an orally active, selective, nonpeptide, angiotensin II AT(1) receptor antagonist. ...In addition, data from several nonblind and double-blind studies indicates that losartan effectively reduces the mean albumin excretion rate. Two double-blind studies s
Losartan is an orally active, selective, nonpeptide, angiotensin II AT(1) receptor antagonist. ...In addition, data from several nonb
Comparison of Blood Pressure Variability Between Losartan and Amlodipine in Essential Hypertension (COMPAS-BPV).
Lee JW, Choi E, Son JW, Youn YJ, Ahn SG, Ahn MS, Kim JY, Lee SH, Yoon J, Ryu DR, Park SM, Hong KS, Yoo BS. Lee JW, et al. Am J Hypertens. 2020 Aug 4;33(8):748-755. doi: 10.1093/ajh/hpaa060. Am J Hypertens. 2020. PMID: 32267481 Clinical Trial.
In home blood pressure analysis, evening day-to-day BPV indexes (SD and ARV) were significantly higher in the losartan group at 6 months. CONCLUSIONS: The lowering effect of the office visit-to-visit SD of SBP was similar between losartan and amlodipine. However, th …
In home blood pressure analysis, evening day-to-day BPV indexes (SD and ARV) were significantly higher in the losartan group at 6 mon …
Aliskiren and losartan trial in non-diabetic chronic kidney disease.
Woo KT, Choong HL, Wong KS, Tan HK, Foo M, Fook-Chong S, Lee EJ, Anantharaman V, Lee GS, Chan CM. Woo KT, et al. J Renin Angiotensin Aldosterone Syst. 2014 Dec;15(4):515-22. doi: 10.1177/1470320313510584. Epub 2014 Apr 17. J Renin Angiotensin Aldosterone Syst. 2014. PMID: 24742970 Free article. Clinical Trial.
INTRODUCTION: This is a report of a clinical trial on the therapeutic efficacy and safety of combined aliskiren and losartan (an angiotensin II receptor blocker (ARB)) versus aliskiren alone and ARB alone in non-diabetic chronic kidney disease (CKD) over a 3-year period. M …
INTRODUCTION: This is a report of a clinical trial on the therapeutic efficacy and safety of combined aliskiren and losartan (an angi …
Losartan improves erectile dysfunction in diabetic patients: a clinical trial.
Chen Y, Cui S, Lin H, Xu Z, Zhu W, Shi L, Yang R, Wang R, Dai Y. Chen Y, et al. Int J Impot Res. 2012 Nov-Dec;24(6):217-20. doi: 10.1038/ijir.2012.4. Epub 2012 Aug 30. Int J Impot Res. 2012. PMID: 22931760 Clinical Trial.
A total of 124 diabetic patients with ED were included in this study and treated with losartan or tadalafil or losartan plus tadalafil or watch for waiting as control for 12 weeks. ...The combination of losartan and tadalafil is more effective than the single …
A total of 124 diabetic patients with ED were included in this study and treated with losartan or tadalafil or losartan plus t …
1,320 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page